MADRIGAL PHARMACEUTICALS, INC.
MDGL · Pharmaceutical Preparations · 23.1M shares · +7%/yr ↑ shares · EDGAR filings ↗
Net buyback after stock comp: -$50M (gross $32K, SBC $50M)
Reference price $495.74 · est. market cap ~$11.4B — last insider sale, 2026-06-01 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
B80Dominant first-mover MASH franchise — Rezdiffra is the first FDA/EU-approved therapy, already at a >$1B annualized run rate with deep cash and a long patent.
Strengths
- $958M revenue in first full year, annualizing >$1B; cash $983M, runway 20.7 quarters
- Wide moat (first/only approved MASH drug, patent to 2045) and positive supporting Phase 2 data
Risks
- Still loss-making (net margin -30%, negative FCF) during commercial/EU build-out
- Accelerated-approval/post-marketing obligations and emerging competition in MASH
Notable findings
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Net lossNet loss (net margin -30.1%)
- Exec changeRecent 8-K item 5.02 8-K ↗
- Cash burnNegative free cash flow (-190.0M)
- Strong balance sheetStrong balance sheet — $984M cash & investments, ~21 quarters of runway
- Trial readout soonUpcoming trial readout ~2026-12 — PHASE3 · NASH
- Notable holderHeld by 6 notable fund(s): STATE STREET CORP, CITADEL ADVISORS LLC, FMR LLC +3 more (as of 2026-03-31)
- Insider sellingInsider selling — 97 open-market sale(s) by 8 insider(s) (cluster of 8 insiders, ~$32M, last 6mo) Form 4 ↗
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-31.3%
Net margin
-30.1%
Return on equity
-47.8%
Return on assets
-22.9%
ROIC
-25.2%
Revenue growth (QoQ)
-3.0%
Debt / equity
0.6×
Current ratio
4.0×
Free cash flow
-$190M
EBITDA
-$299M
Tangible book value
$595M
Cash & investments
$984M
Cash runway
21q
Stock comp / revenue
10.2%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-17 | Levy Richard S | Grant | 454 | — |
| 2026-06-17 | BAKER BROS. ADVISORS LP | Grant | 908 | — |
| 2026-06-17 | BAKER BROS. ADVISORS LP | Grant | 908 | — |
| 2026-06-17 | Taub Rebecca | Grant | 454 | — |
| 2026-06-17 | Brennan Daniel J. | Grant | 404 | — |
| 2026-06-17 | Daly James M | Grant | 454 | — |
| 2026-06-17 | FOUSE JACQUALYN A | Grant | 454 | — |
| 2026-06-01 | Soergel David | Sell | 1.0K | $495.74 |
| 2026-05-22 | Levy Richard S | Sell | 80 | $519.98 |
| 2026-05-22 | Levy Richard S | Sell | 1.5K | $517.59 |
| 2026-05-22 | Levy Richard S | Sell | 439 | $512.50 |
| 2026-05-22 | Levy Richard S | Sell | 40 | $512.97 |
| 2026-05-22 | Levy Richard S | Sell | 343 | $514.67 |
| 2026-05-22 | Levy Richard S | Sell | 657 | $515.92 |
| 2026-05-22 | Levy Richard S | Sell | 723 | $516.87 |
| 2026-05-22 | Levy Richard S | Sell | 610 | $511.40 |
| 2026-05-22 | Levy Richard S | Sell | 782 | $518.76 |
| 2026-05-22 | Levy Richard S | Sell | 40 | $506.68 |
| 2026-05-22 | Levy Richard S | Sell | 320 | $508.24 |
| 2026-05-22 | Levy Richard S | Sell | 151 | $510.36 |
| 2026-05-18 | Soergel David | Sell | 844 | $515.90 |
| 2026-03-06 | Dier Mardi | Sell | 80 | $435.31 |
| 2026-03-06 | Dier Mardi | Sell | 80 | $436.69 |
| 2026-03-06 | Dier Mardi | Sell | 40 | $437.65 |
| 2026-03-06 | Sibold William John | Sell | 1.7K | $431.94 |
| 2026-03-06 | Dier Mardi | Sell | 160 | $434.20 |
| 2026-03-06 | Kelley Shannon T | Sell | 360 | $431.94 |
| 2026-03-06 | Huntsman Carole | Sell | 419 | $431.94 |
| 2026-03-06 | Taub Rebecca | Sell | 491 | $431.94 |
| 2026-03-06 | Dier Mardi | Sell | 160 | $429.00 |
| 2026-03-06 | Dier Mardi | Sell | 80 | $427.85 |
| 2026-03-06 | Dier Mardi | Sell | 420 | $426.86 |
| 2026-03-06 | Dier Mardi | Sell | 40 | $425.08 |
| 2026-03-06 | Dier Mardi | Sell | 646 | $431.94 |
| 2026-03-06 | Dier Mardi | Sell | 40 | $429.58 |
| 2026-03-06 | Dier Mardi | Sell | 120 | $430.90 |
| 2026-03-06 | Dier Mardi | Sell | 116 | $432.56 |
| 2026-03-04 | Kelley Shannon T | Grant | 4.0K | — |
| 2026-03-04 | Sibold William John | Grant | 15K | — |
| 2026-03-04 | Dier Mardi | Grant | 5.2K | — |
| 2026-03-04 | Huntsman Carole | Grant | 4.0K | — |
| 2026-03-04 | Soergel David | Grant | 4.4K | — |
| 2026-03-02 | Dier Mardi | Sell | 1.2K | $427.21 |
| 2026-02-23 | Levy Richard S | Option exercise | 2.5K | $7.36 |
| 2026-01-26 | Huntsman Carole | Sell | 570 | $494.59 |
| 2026-01-26 | Taub Rebecca | Sell | 647 | $492.42 |
| 2026-01-26 | Levy Richard S | Option exercise | 4.0K | $16.46 |
| 2026-01-26 | Huntsman Carole | Sell | 340 | $492.42 |
| 2026-01-26 | Sibold William John | Sell | 1.6K | $492.42 |
| 2026-01-20 | Kelley Shannon T | Sell | 263 | $490.77 |
| 2026-01-20 | Taub Rebecca | Sell | 2.2K | $490.77 |
| 2026-01-20 | Kelley Shannon T | Sell | 429 | $501.40 |
| 2026-01-15 | Thakkar Rita | Grant | 2.4K | — |
| 2026-01-09 | Taub Rebecca | Sell | 30 | $531.05 |
| 2026-01-09 | Taub Rebecca | Sell | 40 | $532.50 |
| 2026-01-09 | Taub Rebecca | Sell | 271 | $534.18 |
| 2026-01-09 | Taub Rebecca | Sell | 89 | $534.93 |
| 2026-01-09 | Taub Rebecca | Sell | 299 | $535.80 |
| 2026-01-09 | Taub Rebecca | Sell | 385 | $536.88 |
| 2026-01-09 | Taub Rebecca | Sell | 40 | $537.84 |
| 2026-01-09 | Taub Rebecca | Sell | 400 | $539.26 |
| 2026-01-09 | Taub Rebecca | Sell | 40 | $540.26 |
| 2026-01-09 | Taub Rebecca | Sell | 400 | $542.72 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 80 | $532.50 |
| 2026-01-09 | FRIEDMAN PAUL A | Option exercise | 280 | $15.80 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 280 | $551.24 |
| 2026-01-09 | FRIEDMAN PAUL A | Option exercise | 25K | $15.80 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 1.5K | $511.98 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 1.1K | $513.11 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 1.3K | $514.68 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 2.0K | $515.81 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 766 | $516.84 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 2.5K | $517.86 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 1.4K | $518.68 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 846 | $519.88 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 681 | $521.03 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 840 | $521.98 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 970 | $523.00 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 1.2K | $524.10 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 2.4K | $525.05 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 1.1K | $526.00 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 1.6K | $526.97 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 575 | $528.18 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 691 | $529.17 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 166 | $529.76 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 280 | $530.69 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 332 | $534.16 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 148 | $535.29 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 473 | $536.02 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 487 | $536.88 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 80 | $537.85 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 480 | $539.23 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 600 | $540.36 |
| 2026-01-09 | FRIEDMAN PAUL A | Sell | 40 | $545.79 |
| 2026-01-09 | Taub Rebecca | Option exercise | 240 | $15.80 |
| 2026-01-09 | Taub Rebecca | Sell | 40 | $545.79 |
| 2026-01-09 | Taub Rebecca | Sell | 200 | $551.24 |
| 2026-01-09 | Taub Rebecca | Option exercise | 18K | $15.80 |
| 2026-01-09 | Taub Rebecca | Sell | 960 | $512.02 |
| 2026-01-09 | Taub Rebecca | Sell | 960 | $513.12 |
| 2026-01-09 | Taub Rebecca | Sell | 937 | $514.63 |
| 2026-01-09 | Taub Rebecca | Sell | 1.6K | $515.82 |
| 2026-01-09 | Taub Rebecca | Sell | 521 | $516.81 |
| 2026-01-09 | Taub Rebecca | Sell | 2.0K | $517.84 |
| 2026-01-09 | Taub Rebecca | Sell | 970 | $518.67 |
| 2026-01-09 | Taub Rebecca | Sell | 539 | $519.89 |
| 2026-01-09 | Taub Rebecca | Sell | 440 | $521.11 |
| 2026-01-09 | Taub Rebecca | Sell | 588 | $521.95 |
| 2026-01-09 | Taub Rebecca | Sell | 732 | $522.98 |
| 2026-01-09 | Taub Rebecca | Sell | 1.3K | $524.06 |
| 2026-01-09 | Taub Rebecca | Sell | 1.5K | $525.12 |
| 2026-01-09 | Taub Rebecca | Sell | 913 | $526.05 |
| 2026-01-09 | Taub Rebecca | Sell | 1.1K | $526.95 |
| 2026-01-09 | Taub Rebecca | Sell | 465 | $528.16 |
| 2026-01-09 | Taub Rebecca | Sell | 554 | $529.28 |
| 2026-01-09 | Taub Rebecca | Sell | 256 | $530.45 |
| 2025-12-10 | FRIEDMAN PAUL A | Sell | 624 | $547.75 |
| 2025-12-10 | FRIEDMAN PAUL A | Sell | 535 | $548.51 |
| 2025-12-10 | FRIEDMAN PAUL A | Option exercise | 25K | $15.80 |
| 2025-12-10 | FRIEDMAN PAUL A | Sell | 409 | $549.99 |
| 2025-12-10 | FRIEDMAN PAUL A | Sell | 4.3K | $550.93 |
| 2025-12-10 | FRIEDMAN PAUL A | Sell | 7.2K | $551.67 |
| 2025-12-10 | FRIEDMAN PAUL A | Sell | 5.5K | $552.74 |
| 2025-12-10 | FRIEDMAN PAUL A | Sell | 5.0K | $553.83 |
| 2025-12-10 | FRIEDMAN PAUL A | Sell | 1.0K | $555.00 |
| 2025-12-10 | FRIEDMAN PAUL A | Sell | 160 | $555.39 |
| 2025-12-10 | Taub Rebecca | Option exercise | 19K | $15.80 |
| 2025-12-10 | Taub Rebecca | Sell | 491 | $547.76 |
| 2025-12-10 | Taub Rebecca | Sell | 369 | $548.56 |
| 2025-12-10 | Taub Rebecca | Sell | 486 | $550.07 |
| 2025-12-10 | Taub Rebecca | Sell | 4.7K | $550.99 |
| 2025-12-10 | Taub Rebecca | Sell | 4.4K | $551.85 |
| 2025-12-10 | Taub Rebecca | Sell | 3.9K | $552.81 |
| 2025-12-10 | Taub Rebecca | Sell | 3.1K | $553.88 |
| 2025-12-10 | Taub Rebecca | Sell | 1.0K | $554.84 |
| 2025-12-10 | Taub Rebecca | Sell | 200 | $555.39 |
| 2025-12-10 | Taub Rebecca | Gift | 5.5K | — |
| 2025-12-04 | Sibold William John | Sell | 2.4K | $575.34 |
| 2025-12-03 | Sibold William John | Option exercise | 50K | — |
| 2025-12-02 | Dier Mardi | Sell | 320 | $570.39 |
| 2025-12-02 | Dier Mardi | Sell | 410 | $571.99 |
| 2025-12-02 | Dier Mardi | Sell | 354 | $573.02 |
| 2025-12-02 | Dier Mardi | Sell | 717 | $574.00 |
| 2025-12-02 | Dier Mardi | Sell | 120 | $574.95 |
| 2025-12-02 | Dier Mardi | Sell | 240 | $576.15 |
| 2025-12-02 | Dier Mardi | Sell | 320 | $577.81 |
| 2025-12-02 | Dier Mardi | Sell | 258 | $578.83 |
| 2025-12-02 | Dier Mardi | Sell | 480 | $579.85 |
| 2025-12-02 | Dier Mardi | Sell | 240 | $585.44 |
| 2025-12-02 | Dier Mardi | Sell | 240 | $587.85 |
| 2025-12-02 | Dier Mardi | Sell | 160 | $589.65 |
| 2025-12-02 | Dier Mardi | Sell | 160 | $590.37 |
| 2025-12-02 | Dier Mardi | Sell | 74 | $595.20 |
| 2025-12-02 | Dier Mardi | Sell | 80 | $596.18 |
| 2025-12-02 | Dier Mardi | Option exercise | 4.2K | $251.63 |
| 2025-11-21 | Huntsman Carole | Sell | 120 | $548.71 |
| 2025-11-21 | Huntsman Carole | Sell | 894 | $550.97 |
| 2025-11-21 | Huntsman Carole | Sell | 144 | $547.27 |
| 2025-11-21 | Huntsman Carole | Sell | 40 | $549.34 |
| 2025-11-21 | Huntsman Carole | Sell | 200 | $552.38 |
| 2025-11-21 | Huntsman Carole | Sell | 40 | $553.23 |
| 2025-11-21 | Huntsman Carole | Sell | 120 | $556.04 |
| 2025-11-21 | Huntsman Carole | Sell | 200 | $559.60 |
| 2025-11-21 | Huntsman Carole | Sell | 80 | $560.62 |
| 2025-11-21 | Huntsman Carole | Sell | 40 | $563.21 |
| 2025-11-21 | Huntsman Carole | Sell | 80 | $564.57 |
| 2025-11-13 | Levy Richard S | Option exercise | 2.5K | $7.36 |
| 2025-11-13 | Levy Richard S | Option exercise | 6.0K | $16.46 |
| 2025-11-13 | Levy Richard S | Sell | 146 | $514.67 |
| 2025-11-13 | Levy Richard S | Sell | 919 | $515.64 |
| 2025-11-13 | Levy Richard S | Sell | 645 | $517.51 |
| 2025-11-13 | Levy Richard S | Sell | 835 | $518.53 |
| 2025-11-13 | Levy Richard S | Sell | 1.4K | $519.67 |
| 2025-11-13 | Levy Richard S | Sell | 308 | $520.68 |
| 2025-11-13 | Levy Richard S | Sell | 1.1K | $521.79 |
| 2025-11-13 | Levy Richard S | Sell | 1.4K | $522.70 |
| 2025-11-13 | Levy Richard S | Sell | 811 | $523.66 |
| 2025-11-13 | Levy Richard S | Sell | 153 | $524.49 |
| 2025-11-13 | Levy Richard S | Sell | 120 | $526.68 |
| 2025-11-13 | Levy Richard S | Sell | 200 | $527.85 |
| 2025-11-13 | Levy Richard S | Sell | 440 | $528.60 |
| 2025-11-13 | Levy Richard S | Sell | 40 | $530.21 |
| 2025-11-05 | BATE KENNETH | Option exercise | 5.5K | $9.45 |
| 2025-11-05 | BATE KENNETH | Option exercise | 10K | $303.79 |
| 2025-11-05 | BATE KENNETH | Option exercise | 1.1K | $280.04 |
| 2025-11-05 | BATE KENNETH | Sell | 1.8K | $480.24 |
| 2025-11-05 | BATE KENNETH | Sell | 3.3K | $481.13 |
| 2025-11-05 | BATE KENNETH | Sell | 1.3K | $482.41 |
| 2025-11-05 | BATE KENNETH | Sell | 2.1K | $483.41 |
| 2025-11-05 | BATE KENNETH | Sell | 1.9K | $484.78 |
| 2025-11-05 | BATE KENNETH | Sell | 1.0K | $485.54 |
| 2025-11-05 | BATE KENNETH | Sell | 827 | $486.73 |
| 2025-11-05 | BATE KENNETH | Sell | 2.8K | $487.49 |
| 2025-11-05 | BATE KENNETH | Sell | 696 | $489.09 |
| 2025-11-05 | BATE KENNETH | Sell | 933 | $489.95 |
| 2025-11-05 | BATE KENNETH | Sell | 30 | $490.98 |
| 2025-09-09 | Sibold William John | Sell | 7.3K | $445.63 |
| 2025-08-21 | Sibold William John | Sell | 6.5K | $400.03 |
| 2025-08-21 | Sibold William John | Sell | 1.1K | $401.00 |
| 2025-08-20 | BAKER BROS. ADVISORS LP | Buy | 2.8K | $382.82 |
| 2025-08-20 | BAKER BROS. ADVISORS LP | Buy | 480 | $380.44 |
| 2025-08-20 | BAKER BROS. ADVISORS LP | Buy | 5.2K | $380.44 |
| 2025-08-20 | BAKER BROS. ADVISORS LP | Buy | 176 | $380.78 |
| 2025-08-20 | BAKER BROS. ADVISORS LP | Buy | 1.9K | $380.78 |
| 2025-08-20 | BAKER BROS. ADVISORS LP | Buy | 873 | $381.12 |
| 2025-08-20 | BAKER BROS. ADVISORS LP | Buy | 9.5K | $381.12 |
| 2025-08-20 | BAKER BROS. ADVISORS LP | Buy | 105 | $382.29 |
| 2025-08-20 | BAKER BROS. ADVISORS LP | Buy | 1.1K | $382.29 |
| 2025-08-20 | BAKER BROS. ADVISORS LP | Buy | 262 | $382.82 |
| 2025-08-20 | BAKER BROS. ADVISORS LP | Buy | 373 | $383.79 |
| 2025-08-20 | BAKER BROS. ADVISORS LP | Buy | 4.0K | $383.79 |
| 2025-08-20 | BAKER BROS. ADVISORS LP | Buy | 1.2K | $385.06 |
| 2025-08-20 | BAKER BROS. ADVISORS LP | Buy | 14K | $385.06 |
| 2025-08-20 | BAKER BROS. ADVISORS LP | Buy | 409 | $387.07 |
| 2025-08-20 | BAKER BROS. ADVISORS LP | Buy | 4.4K | $387.07 |
| 2025-08-20 | BAKER BROS. ADVISORS LP | Buy | 34 | $389.00 |
| 2025-08-20 | BAKER BROS. ADVISORS LP | Buy | 366 | $389.00 |
| 2025-08-20 | BAKER BROS. ADVISORS LP | Buy | 231 | $389.89 |
| 2025-08-20 | BAKER BROS. ADVISORS LP | Buy | 2.5K | $389.89 |
| 2025-08-20 | BAKER BROS. ADVISORS LP | Buy | 862 | $392.24 |
| 2025-08-20 | BAKER BROS. ADVISORS LP | Buy | 9.4K | $392.24 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 84 | $355.00 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 916 | $355.00 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 1.9K | $353.88 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 177 | $353.88 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 27K | $372.87 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 767 | $357.02 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 8.3K | $357.02 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 228 | $358.21 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 2.5K | $358.21 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 784 | $359.39 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 8.5K | $359.39 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 502 | $361.37 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 5.4K | $361.37 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 675 | $374.43 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 7.3K | $374.43 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 2.5K | $372.87 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 515 | $362.39 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 5.6K | $362.39 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 255 | $363.75 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 2.8K | $363.75 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 211 | $366.30 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 2.3K | $366.30 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 442 | $367.77 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 4.8K | $367.77 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 131 | $368.84 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 1.4K | $368.84 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 253 | $369.33 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 2.7K | $369.33 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 506 | $371.00 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 5.5K | $371.00 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 933 | $372.16 |
| 2025-08-18 | BAKER BROS. ADVISORS LP | Buy | 10K | $372.16 |
| 2025-08-18 | Kelley Shannon T | Sell | 458 | $358.66 |
| 2025-08-18 | Kelley Shannon T | Sell | 126 | $369.64 |
| 2025-08-18 | Kelley Shannon T | Sell | 84 | $370.06 |
| 2025-08-18 | Kelley Shannon T | Sell | 84 | $371.35 |
| 2025-08-18 | Kelley Shannon T | Sell | 252 | $372.44 |
| 2025-08-18 | Kelley Shannon T | Sell | 68 | $374.13 |
| 2025-08-18 | Kelley Shannon T | Sell | 190 | $375.75 |
| 2025-08-18 | Kelley Shannon T | Sell | 42 | $376.62 |
| 2025-08-15 | BATE KENNETH | Option exercise | 10K | $16.46 |
| 2025-08-15 | BATE KENNETH | Sell | 2.3K | $363.41 |
| 2025-08-15 | BATE KENNETH | Sell | 2.5K | $364.24 |
| 2025-08-15 | BATE KENNETH | Sell | 2.6K | $365.33 |
| 2025-08-15 | BATE KENNETH | Sell | 600 | $366.14 |
| 2025-08-15 | BATE KENNETH | Sell | 1.1K | $367.63 |
| 2025-08-15 | BATE KENNETH | Sell | 896 | $368.56 |
| 2025-08-13 | FRIEDMAN PAUL A | Sell | 24K | $373.35 |
| 2025-08-13 | FRIEDMAN PAUL A | Option exercise | 129K | $9.45 |
| 2025-08-13 | FRIEDMAN PAUL A | Sell | 1.6K | $358.23 |
| 2025-08-13 | FRIEDMAN PAUL A | Sell | 455 | $359.31 |
| 2025-08-13 | FRIEDMAN PAUL A | Sell | 3.2K | $360.27 |
| 2025-08-13 | FRIEDMAN PAUL A | Sell | 1.8K | $361.13 |
| 2025-08-13 | FRIEDMAN PAUL A | Sell | 1.4K | $362.29 |
| 2025-08-13 | FRIEDMAN PAUL A | Sell | 2.6K | $363.08 |
| 2025-08-13 | FRIEDMAN PAUL A | Sell | 3.5K | $364.02 |
| 2025-08-13 | FRIEDMAN PAUL A | Sell | 1.7K | $365.19 |
| 2025-08-13 | FRIEDMAN PAUL A | Sell | 3.2K | $366.22 |
| 2025-08-13 | FRIEDMAN PAUL A | Sell | 7.1K | $367.31 |
| 2025-08-13 | FRIEDMAN PAUL A | Sell | 6.8K | $368.34 |
| 2025-08-13 | FRIEDMAN PAUL A | Sell | 8.0K | $369.44 |
| 2025-08-13 | FRIEDMAN PAUL A | Sell | 7.9K | $370.44 |
| 2025-08-13 | FRIEDMAN PAUL A | Sell | 23K | $371.53 |
| 2025-08-13 | FRIEDMAN PAUL A | Sell | 29K | $372.39 |
| 2025-08-13 | FRIEDMAN PAUL A | Sell | 4.2K | $374.38 |
| 2025-08-12 | FRIEDMAN PAUL A | Sell | 8.4K | $357.93 |
| 2025-08-12 | FRIEDMAN PAUL A | Sell | 600 | $359.81 |
| 2025-08-12 | FRIEDMAN PAUL A | Sell | 1.4K | $352.61 |
| 2025-08-12 | FRIEDMAN PAUL A | Sell | 4.8K | $354.06 |
| 2025-08-12 | Taub Rebecca | Option exercise | 43K | $9.45 |
| 2025-08-12 | Taub Rebecca | Sell | 3.6K | $350.87 |
| 2025-08-12 | Taub Rebecca | Sell | 2.9K | $351.60 |
| 2025-08-12 | Taub Rebecca | Sell | 1.2K | $352.45 |
| 2025-08-12 | Taub Rebecca | Sell | 4.6K | $354.04 |
| 2025-08-12 | Taub Rebecca | Sell | 6.5K | $354.97 |
| 2025-08-12 | Taub Rebecca | Sell | 5.8K | $355.95 |
| 2025-08-12 | Taub Rebecca | Sell | 4.9K | $356.88 |
| 2025-08-12 | Taub Rebecca | Sell | 6.7K | $357.85 |
| 2025-08-12 | Taub Rebecca | Sell | 6.5K | $358.81 |
| 2025-08-12 | Taub Rebecca | Sell | 700 | $359.71 |
| 2025-08-12 | FRIEDMAN PAUL A | Sell | 6.5K | $355.00 |
| 2025-08-12 | FRIEDMAN PAUL A | Sell | 5.2K | $355.97 |
| 2025-08-12 | FRIEDMAN PAUL A | Sell | 5.1K | $356.94 |
| 2025-08-12 | FRIEDMAN PAUL A | Sell | 5.0K | $358.83 |
| 2025-08-12 | FRIEDMAN PAUL A | Option exercise | 44K | $9.45 |
| 2025-08-12 | FRIEDMAN PAUL A | Sell | 3.3K | $350.93 |
| 2025-08-12 | FRIEDMAN PAUL A | Sell | 3.2K | $351.59 |
| 2025-08-11 | Taub Rebecca | Option exercise | 3.2K | $9.45 |
| 2025-08-11 | Taub Rebecca | Sell | 3.0K | $350.18 |
| 2025-08-11 | Taub Rebecca | Sell | 220 | $351.02 |
| 2025-08-11 | FRIEDMAN PAUL A | Sell | 300 | $351.04 |
| 2025-08-11 | FRIEDMAN PAUL A | Sell | 2.9K | $350.19 |
| 2025-08-11 | FRIEDMAN PAUL A | Option exercise | 3.2K | $9.45 |
| 2025-08-01 | Brennan Daniel J. | Grant | 967 | — |
| 2025-07-18 | FRIEDMAN PAUL A | Sell | 1.4K | $350.03 |
| 2025-07-18 | FRIEDMAN PAUL A | Option exercise | 1.4K | $9.45 |
| 2025-07-18 | Taub Rebecca | Sell | 1.0K | $350.00 |
| 2025-07-18 | Taub Rebecca | Option exercise | 1.0K | $9.45 |
| 2025-07-17 | FRIEDMAN PAUL A | Option exercise | 2.7K | $9.45 |
| 2025-07-17 | Taub Rebecca | Option exercise | 2.7K | $9.45 |
| 2025-07-17 | Taub Rebecca | Sell | 600 | $351.50 |
| 2025-07-17 | FRIEDMAN PAUL A | Sell | 700 | $351.57 |
| 2025-07-17 | FRIEDMAN PAUL A | Sell | 2.0K | $350.10 |
| 2025-07-17 | Taub Rebecca | Sell | 2.1K | $350.09 |
| 2025-07-16 | FRIEDMAN PAUL A | Sell | 2.1K | $352.67 |
| 2025-07-16 | FRIEDMAN PAUL A | Option exercise | 26K | $9.45 |
| 2025-07-16 | FRIEDMAN PAUL A | Sell | 5.5K | $350.17 |
| 2025-07-16 | FRIEDMAN PAUL A | Sell | 2.4K | $351.38 |
| 2025-07-16 | FRIEDMAN PAUL A | Sell | 2.3K | $353.82 |
| 2025-07-16 | FRIEDMAN PAUL A | Sell | 6.9K | $354.65 |
| 2025-07-16 | FRIEDMAN PAUL A | Sell | 5.8K | $355.61 |
| 2025-07-16 | FRIEDMAN PAUL A | Sell | 1.2K | $356.62 |
| 2025-07-16 | Taub Rebecca | Option exercise | 26K | $9.45 |
| 2025-07-16 | Taub Rebecca | Sell | 6.0K | $350.19 |
| 2025-07-16 | Taub Rebecca | Sell | 1.9K | $351.37 |
| 2025-07-16 | Taub Rebecca | Sell | 2.4K | $352.64 |
| 2025-07-16 | Taub Rebecca | Sell | 2.6K | $353.82 |
| 2025-07-16 | Taub Rebecca | Sell | 5.8K | $354.61 |
| 2025-07-16 | Taub Rebecca | Sell | 6.4K | $355.61 |
| 2025-07-16 | Taub Rebecca | Sell | 1.4K | $356.52 |
| 2025-06-20 | FOUSE JACQUALYN A | Grant | 203 | — |
| 2025-06-20 | Daly James M | Grant | 715 | — |
| 2025-06-20 | FRIEDMAN PAUL A | Grant | 715 | — |
| 2025-06-20 | BATE KENNETH | Grant | 715 | — |
| 2025-06-20 | Levy Richard S | Grant | 715 | — |
| 2025-06-20 | BAKER BROS. ADVISORS LP | Grant | 1.4K | — |
| 2025-06-20 | BAKER BROS. ADVISORS LP | Grant | 1.4K | — |
| 2025-05-15 | Soergel David | Grant | 7.5K | — |
| 2025-04-10 | Levy Richard S | Option exercise | 9.5K | $65.06 |
| 2025-03-13 | CRAVES FRED B | Sell | 2.0K | $322.45 |
| 2025-03-13 | CRAVES FRED B | Sell | 900 | $324.69 |
| 2025-03-13 | CRAVES FRED B | Sell | 800 | $325.63 |
| 2025-03-13 | CRAVES FRED B | Sell | 1.0K | $327.63 |
| 2025-03-13 | CRAVES FRED B | Sell | 400 | $328.68 |
| 2025-03-13 | CRAVES FRED B | Sell | 967 | $329.86 |
| 2025-03-13 | CRAVES FRED B | Sell | 75 | $330.23 |
| 2025-03-13 | CRAVES FRED B | Option exercise | 7.7K | $65.06 |
| 2025-03-13 | CRAVES FRED B | Sell | 1.6K | $323.47 |
| 2025-03-12 | CRAVES FRED B | Sell | 2.4K | $332.38 |
| 2025-03-12 | CRAVES FRED B | Option exercise | 1.7K | $65.06 |
| 2025-03-12 | CRAVES FRED B | Option exercise | 6.0K | $111.06 |
| 2025-03-12 | CRAVES FRED B | Sell | 1.6K | $330.54 |
| 2025-03-12 | CRAVES FRED B | Sell | 2.8K | $331.36 |
| 2025-03-12 | CRAVES FRED B | Sell | 800 | $333.66 |
| 2025-03-12 | CRAVES FRED B | Sell | 200 | $334.97 |
| 2025-03-10 | Dier Mardi | Sell | 258 | $323.04 |
| 2025-03-10 | FOUSE JACQUALYN A | Grant | 894 | — |
| 2025-03-05 | Waltermire Robert E. | Sell | 900 | $335.15 |
| 2025-03-05 | Sibold William John | Grant | 13K | — |
| 2025-03-05 | Dier Mardi | Grant | 3.8K | — |
| 2025-03-05 | Waltermire Robert E. | Option exercise | 6.8K | $87.92 |
| 2025-03-05 | Waltermire Robert E. | Option exercise | 7.3K | $87.09 |
| 2025-03-05 | Waltermire Robert E. | Sell | 1.8K | $336.78 |
| 2025-03-05 | Waltermire Robert E. | Sell | 1.1K | $338.09 |
| 2025-03-05 | Waltermire Robert E. | Sell | 400 | $339.68 |
| 2025-03-05 | Waltermire Robert E. | Sell | 1.7K | $340.75 |
| 2025-03-05 | Waltermire Robert E. | Sell | 1.0K | $341.84 |
| 2025-03-05 | Waltermire Robert E. | Sell | 1.1K | $342.90 |
| 2025-03-05 | Waltermire Robert E. | Sell | 4.7K | $343.85 |
| 2025-03-05 | Waltermire Robert E. | Sell | 1.4K | $344.76 |
| 2025-03-05 | Waltermire Robert E. | Grant | 2.1K | — |
| 2025-03-05 | Taub Rebecca | Grant | 4.4K | — |
| 2025-03-05 | Kelley Shannon T | Grant | 3.2K | — |
| 2025-03-05 | Huntsman Carole | Grant | 3.4K | — |
| 2025-03-03 | Huntsman Carole | Sell | 300 | $320.21 |
| 2025-03-03 | Kelley Shannon T | Sell | 415 | $335.00 |
| 2025-03-03 | Huntsman Carole | Sell | 200 | $323.65 |
| 2025-03-03 | Huntsman Carole | Sell | 200 | $324.59 |
| 2025-03-03 | Huntsman Carole | Sell | 100 | $326.34 |
| 2025-03-03 | Huntsman Carole | Sell | 100 | $327.49 |
| 2025-03-03 | Huntsman Carole | Sell | 100 | $329.64 |
| 2025-03-03 | Huntsman Carole | Sell | 563 | $335.00 |
| 2025-03-03 | Huntsman Carole | Sell | 200 | $314.74 |
| 2025-03-03 | Dier Mardi | Sell | 1.2K | $325.89 |
| 2025-03-03 | Dier Mardi | Sell | 774 | $323.54 |
| 2025-03-03 | Huntsman Carole | Sell | 71 | $313.08 |
| 2025-02-28 | Waltermire Robert E. | Sell | 1.1K | $340.99 |
| 2025-02-28 | Waltermire Robert E. | Sell | 175 | $341.55 |
| 2025-02-27 | BATE KENNETH | Sell | 238 | $353.83 |
| 2025-02-27 | BATE KENNETH | Sell | 8.5K | $355.08 |
| 2025-02-27 | BATE KENNETH | Sell | 2.0K | $359.21 |
| 2025-02-27 | BATE KENNETH | Sell | 2.0K | $357.27 |
| 2025-02-27 | BATE KENNETH | Sell | 2.8K | $356.51 |
| 2025-02-27 | BATE KENNETH | Sell | 3.5K | $358.33 |
| 2025-02-27 | Sibold William John | Option exercise | 50K | — |
| 2025-02-27 | Daly James M | Option exercise | 9.5K | $65.06 |
| 2025-02-27 | Daly James M | Option exercise | 6.0K | $111.06 |
| 2025-02-27 | Daly James M | Sell | 398 | $346.90 |
| 2025-02-27 | BATE KENNETH | Sell | 216 | $360.07 |
| 2025-02-27 | Daly James M | Sell | 14K | $347.39 |
| 2025-02-27 | Daly James M | Sell | 770 | $348.94 |
| 2025-02-27 | BATE KENNETH | Option exercise | 6.0K | $111.06 |
| 2025-02-27 | BATE KENNETH | Option exercise | 9.5K | $65.06 |
| 2025-02-27 | BATE KENNETH | Option exercise | 4.5K | $9.45 |
| 2025-02-27 | BATE KENNETH | Sell | 100 | $351.01 |
| 2025-02-27 | BATE KENNETH | Sell | 500 | $351.99 |
| 2025-01-24 | Taub Rebecca | Sell | 648 | $335.24 |
| 2025-01-24 | Waltermire Robert E. | Sell | 103 | $335.24 |
| 2025-01-24 | Huntsman Carole | Sell | 347 | $335.24 |
| 2025-01-24 | Sibold William John | Sell | 1.6K | $335.24 |
| 2025-01-17 | Taub Rebecca | Sell | 1.7K | $273.41 |
| 2025-01-17 | Kelley Shannon T | Sell | 277 | $273.41 |
| 2025-01-17 | Waltermire Robert E. | Sell | 442 | $273.41 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07541469 ↗ | Rezdiffra Pregnancy and Lactation Registry MASH - Metabolic Dysfunction-Associated Steatohepatitis | — | Recruiting | 2030-04-08 |
| NCT07335601 ↗ | Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH MASH - Metabolic Dysfunction-Associated Steatohepatitis | PHASE2 | Recruiting | 2028-08-01 |
| NCT03900429 ↗ | A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis NASH - Nonalcoholic Steatohepatitis | PHASE3 | Active Not Recruiting | 2028-01-01 |
| NCT04951219 ↗ | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) Non-Alcoholic Fatty Liver Disease | PHASE3 | Active Not Recruiting | 2027-03-01 |
| NCT05500222 ↗ | A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) NASH, Cirrhosis, Liver | PHASE3 | Active Not Recruiting | 2026-12-01 |
| NCT06397872 ↗ | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function Renal Impairment | PHASE1 | Completed | 2024-09-16 |
| NCT04197479 ↗ | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients Non-Alcoholic Fatty Liver Disease | PHASE3 | Completed | 2023-01-06 |
| NCT04643795 ↗ | Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis | PHASE1 | Completed | 2021-08-04 |
| NCT04671069 ↗ | Drug Interaction Study of MGL-3196 With Clopidogrel Healthy | PHASE1 | Completed | 2019-08-30 |
| NCT04671056 ↗ | Drug Interaction Study of MGL-3196 With Pioglitazone Healthy | PHASE1 | Completed | 2018-12-11 |
| NCT03413124 ↗ | Bioavailability Study of MGL-3196 Tablets Compared to Capsules Healthy | PHASE1 | Completed | 2018-02-17 |
| NCT03038022 ↗ | Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Heterozygous Familial Hypercholesterolemia | PHASE2 | Completed | 2018-01-15 |
| NCT02912260 ↗ | Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH) Non-alcoholic Steatohepatitis | PHASE2 | Completed | 2017-10-25 |
| NCT03220165 ↗ | Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196 Healthy | PHASE1 | Completed | 2017-09-03 |
| NCT02749578 ↗ | Drug Interaction Study of MGL-3196 With Atorvastatin Healthy | PHASE1 | Completed | 2016-05-01 |
| NCT02542969 ↗ | Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin Healthy | PHASE1 | Completed | 2015-10-01 |
| NCT01519531 ↗ | Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects Drug Safety | PHASE1 | Completed | 2012-11-01 |
| NCT01367873 ↗ | Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects Drug Safety | PHASE1 | Completed | 2011-10-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Supply chain
Customers (0)
Suppliers (6)
- Roche
- CSPC Pharmaceutical Group Limited
- Suzhou Ribo Life Science Co. Ltd.
- Ribocure Pharmaceuticals AB
- Blue Owl Capital Corporation
- LSI Financing LLC
Named in the 10-K; linked when we track them.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-17 | Exec/director changeShareholder voteExhibits | filing ↗ |
| 2026-05-06 | ResultsExhibits | filing ↗ |
| 2026-04-28 | Exec/director change | filing ↗ |
| 2026-02-19 | ResultsExhibits | filing ↗ |
| 2026-01-30 | Material agreementExhibits | filing ↗ |
| 2025-12-11 | Exec/director change | filing ↗ |
| 2025-11-04 | ResultsExhibits | filing ↗ |
| 2025-08-05 | ResultsExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-17 | 2026-06-16 | 0001104659-26-075130 ↗ |
| 10-Q | 2026-05-06 | 2026-03-31 | 0001628280-26-030947 ↗ |
| 8-K | 2026-05-06 | 2026-05-06 | 0001628280-26-030896 ↗ |
| 8-K | 2026-04-28 | 2026-04-22 | 0001628280-26-027956 ↗ |
| 10-K | 2026-02-19 | 2025-12-31 | 0001628280-26-009514 ↗ |
| 8-K | 2026-02-19 | 2026-02-19 | 0001628280-26-009476 ↗ |
| 8-K | 2026-01-30 | 2026-01-29 | 0001104659-26-008698 ↗ |
| 8-K | 2025-12-11 | 2025-12-05 | 0001628280-25-056533 ↗ |
| 8-K | 2025-11-04 | 2025-11-04 | 0001628280-25-048525 ↗ |
| 10-Q | 2025-11-04 | 2025-09-30 | 0001628280-25-048559 ↗ |
| 8-K | 2025-08-05 | 2025-08-05 | 0001628280-25-037596 ↗ |
| 10-Q | 2025-08-05 | 2025-06-30 | 0001628280-25-037613 ↗ |